Jazz Pharmaceuticals plc – (JAZZ) Upgraded at Vetr Inc.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) was upgraded by Vetr from a “buy” rating to a “strong-buy” rating in a note issued to investors on Monday. The firm currently has a $161.19 price target on the specialty pharmaceutical company’s stock. Vetr‘s price objective indicates a potential upside of 5.46% from the company’s current price.

Other analysts have also recently issued research reports about the stock. TheStreet raised shares of Jazz Pharmaceuticals plc – from a “c+” rating to a “b-” rating in a research note on Tuesday, March 28th. Guggenheim reiterated a “buy” rating on shares of Jazz Pharmaceuticals plc – in a report on Thursday, February 16th. Mizuho boosted their target price on shares of Jazz Pharmaceuticals plc – from $127.00 to $152.00 and gave the company a “buy” rating in a report on Tuesday, February 21st. BMO Capital Markets reiterated a “positive” rating and issued a $192.00 target price on shares of Jazz Pharmaceuticals plc – in a report on Monday, March 20th. Finally, Goldman Sachs Group Inc reiterated a “buy” rating and issued a $170.00 target price on shares of Jazz Pharmaceuticals plc – in a report on Wednesday, January 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and fourteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $181.23.

Analyst Recommendations for Jazz Pharmaceuticals plc - (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 0.89% on Monday, hitting $152.84. The company’s stock had a trading volume of 436,725 shares. Jazz Pharmaceuticals plc – has a 12 month low of $95.80 and a 12 month high of $160.00. The firm has a market cap of $9.13 billion, a price-to-earnings ratio of 23.84 and a beta of 1.22. The firm has a 50 day moving average of $143.48 and a 200 day moving average of $123.54.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, February 28th. The specialty pharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.65 by $0.74. Jazz Pharmaceuticals plc – had a net margin of 24.81% and a return on equity of 30.50%. The business had revenue of $396.62 million for the quarter, compared to analysts’ expectations of $398.91 million. During the same period in the prior year, the company posted $2.60 EPS. The firm’s revenue was up 16.4% on a year-over-year basis. Equities research analysts forecast that Jazz Pharmaceuticals plc – will post $11.10 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This story was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.themarketsdaily.com/2017/04/21/jazz-pharmaceuticals-plc-jazz-upgraded-at-vetr-inc-updated.html.

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, April 11th. The shares were sold at an average price of $152.12, for a total value of $152,120.00. Following the transaction, the chief executive officer now directly owns 308,491 shares of the company’s stock, valued at approximately $46,927,650.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $134.55, for a total transaction of $26,910.00. Following the completion of the transaction, the senior vice president now directly owns 16,486 shares in the company, valued at $2,218,191.30. The disclosure for this sale can be found here. Over the last three months, insiders sold 13,942 shares of company stock worth $2,098,147. Insiders own 3.90% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Howard Hughes Medical Institute bought a new position in Jazz Pharmaceuticals plc – during the third quarter worth approximately $112,000. Brave Asset Management Inc increased its position in Jazz Pharmaceuticals plc – by 540.0% in the third quarter. Brave Asset Management Inc now owns 960 shares of the specialty pharmaceutical company’s stock worth $117,000 after buying an additional 810 shares during the period. Daiwa Securities Group Inc. increased its position in Jazz Pharmaceuticals plc – by 10.7% in the third quarter. Daiwa Securities Group Inc. now owns 1,550 shares of the specialty pharmaceutical company’s stock worth $188,000 after buying an additional 150 shares during the period. Mn Services Vermogensbeheer B.V. increased its position in shares of Jazz Pharmaceuticals plc – by 2.4% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,557 shares of the specialty pharmaceutical company’s stock valued at $189,000 after buying an additional 37 shares during the last quarter. Finally, FNY Managed Accounts LLC acquired a new position in shares of Jazz Pharmaceuticals plc – during the third quarter valued at about $204,000. 88.56% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals plc –

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

5 Day Chart for NASDAQ:JAZZ

To view Vetr’s full report, visit Vetr’s official website.

Receive News & Ratings for Jazz Pharmaceuticals plc - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals plc - and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply